E-Z-EM, Inc.: News Release

                     ANGIODYNAMICS, INCORPORATED

October 9, 1997

PRESS RELEASE
                                        Contact:
                                        Michael P. Cody
FOR IMMEDIATE RELEASE                   Director, Corporate Communications
                                        (518) 798-1215, Ext. 140

            PULSE*SPRAY INJECTOR IS PURCHASED
            BY COLUMBlA/HCA HEALTHCARE CORPORATION

Queensbury, NY, October 9, 1997. AngioDynamics, a wholly owned subsidiary of
E-Z-EM, Inc. (Amex: EZM.A and EZM.B) announced today its first United States
sale and installation of its recently FDA cleared Pulse*Spray Injector to
Columbia/HCA's Tulsa Regional Medical Center of Tulsa, Oklahoma.

The Pulse*Spray Injector is an automated method of delivering blood clot
dissolving drugs through the AngioDynamics PRO catheters. The system
automatically and consistently delivers precise amounts of the drug into the
clot with a physician-specific drug delivery protocol. The injector is small
and may be easily transported for drug delivery in the patient's room, thus
freeing expensive room time in radiology.

George Erbacher, D.O., chief of Interventional Radiology at the Columbia Tulsa
Regional Medical Center said: "Dissolving the clot will be faster and more
accurate. In addition to the speed of the procedure and short hospital stays,
the use of the Pulse*Spray Injector will result in decreased or no time in the
lCU, which should result in tremendous savings for our patients."

Dr. Erbacher added: "Studies show that treatment of acute arterial clots with
urokinase result in a 40 percent less mortality rate than treating with
surgery alone. We strive to use urokinase first to uncover the underlying
cause of clotted vessels then use the surgery or other catheter techniques to
save legs. I think the Pulse*Spray Injector will give us an even better chance
of avoiding unnecessary surgery, especially amputations."

According to Columbia sources Dr. Erbacher plans to begin a study on the
injector's effectiveness in treating illiofemoral Deep Vein Thrombus (clots
located in the deep veins located above and behind the knee), an area which
has become his specialty. In the study, Erbacher plans to compare the
effectiveness of the procedure with traditional methods. It will be the first
study of its kind in the country.

Eamonn P. Hobbs, president and chief executive officer of AngioDynamics
said: "We are delighted that Columbia/HCA is our first United States customer.
Dr. Erbacher has been keenly interested in our injector for over three years.
It is gratifying that once we received FDA clearance, Columbia/HCA acted
instantly to purchase our product."

Mr. Hobbs added: "We in the United States are fortunate that our health care
system pays for aggressive drug therapy of clotted arteries and veins-although
at a high cost. We are convinced that our Pulse*Spray Injector is going to
help lower these costs. This is an example of a good product that should
result in better medicine, satisfied patients and lower costs."

ANGIODYNAMICS, PRO and PULSE*SPRAY are registered trademarks of AngioDynamics,
Inc.


The statements made in this press release contain certain forward-looking
statements that involve a number of risks and uncertainties. Actual events or
results may differ from the company's expectations. In addition to matters
described in this release. Future actions by the FDA, results of pending or
future clinical trials, as well as the risk factors listed from time to time in
the SEC filings of E-Z-EM, Inc. including but not limited to its Annual Report
on Form 10-K, may affect the actual results achieved by the company.

Ends